The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.

Saved in:
Bibliographic Details
Title: The NPR1 agonist antibody XXB750 in heart failure: a phase 2 randomized trial.
Authors: Solomon SD; The Cardiovascular Division, Mass General Brigham, Harvard Medical School, Boston, MA, USA. ssolomon@bwh.harvard.edu., McMurray JJV; University of Glasgow, Glasgow, UK., Felker GM; Duke University, Durham, NC, USA., Januzzi JL; The Cardiovascular Division, Mass General Brigham, Harvard Medical School, Boston, MA, USA., Lam CSP; Duke National University of Singapore, Singapore, Singapore., Voors AA; University of Groningen, Groningen, the Netherlands., Claggett B; The Cardiovascular Division, Mass General Brigham, Harvard Medical School, Boston, MA, USA., Nuehrenberg TG; Novartis Pharma AG, Basel, Switzerland., Rizkala AR; Novartis Pharmaceuticals, East Hanover, NJ, USA., Koch C; Novartis Pharma AG, Basel, Switzerland., Zhu W; Novartis Pharmaceuticals UK Ltd, London, UK., Lefkowitz MP; Novartis Pharmaceuticals, East Hanover, NJ, USA.
Source: Nature medicine [Nat Med] 2026 May; Vol. 32 (5), pp. 1694-1700. Date of Electronic Publication: 2026 Mar 30.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1546-170X
DOI:10.1038/s41591-026-04313-w